c-Met Overexpression in Cervical Cancer, a Prognostic Factor and a Potential Molecular Therapeutic Target

MLA

Refaat, Tamer, et al. “C-Met Overexpression in Cervical Cancer, a Prognostic Factor and a Potential Molecular Therapeutic Target.” American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 40, no. 6, Dec. 2017, pp. 590–97. EBSCOhost, https://doi.org/10.1097/COC.0000000000000203.

APA

Refaat, T., Donnelly, E. D., Sachdev, S., Parimi, V., El Achy, S., Dalal, P., Farouk, M., Berg, N., Helenowski, I., Gross, J. P., Lurain, J., Strauss, J. B., Woloschak, G., Wei, J.-J., & Small, W. (2017). c-Met Overexpression in Cervical Cancer, a Prognostic Factor and a Potential Molecular Therapeutic Target. American Journal of Clinical Oncology: Cancer Clinical Trials, 40(6), 590–597. https://doi.org/10.1097/COC.0000000000000203

Chicago

Refaat, Tamer, Eric D. Donnelly, Sean Sachdev, Vamsi Parimi, Samar El Achy, Prarthana Dalal, Mohamed Farouk, et al. 2017. “C-Met Overexpression in Cervical Cancer, a Prognostic Factor and a Potential Molecular Therapeutic Target.” American Journal of Clinical Oncology: Cancer Clinical Trials 40 (6): 590–97. doi:10.1097/COC.0000000000000203.